Bayer Ready To File Elinzanetant After It Clears Third Phase III Hurdle
Will Compete With Sluggish Astellas Competitor
Bayer will submit its non-hormonal treatment for vasomotor symptoms associated with menopause for approvals this year, still eyeing €1bn-plus in peak sales despite a rival’s slow start.
